320 related articles for article (PubMed ID: 21332761)
1. Enhanced activity of antifungal drugs using natural phenolics against yeast strains of Candida and Cryptococcus.
Faria NC; Kim JH; Gonçalves LA; Martins Mde L; Chan KL; Campbell BC
Lett Appl Microbiol; 2011 May; 52(5):506-13. PubMed ID: 21332761
[TBL] [Abstract][Full Text] [Related]
2. Identification of Off-Patent Drugs That Show Synergism with Amphotericin B or That Present Antifungal Action against Cryptococcus neoformans and
Rossi SA; de Oliveira HC; Agreda-Mellon D; Lucio J; Mendes-Giannini MJS; García-Cambero JP; Zaragoza O
Antimicrob Agents Chemother; 2020 Mar; 64(4):. PubMed ID: 31988099
[TBL] [Abstract][Full Text] [Related]
3. In vitro determination of optimal antifungal combinations against Cryptococcus neoformans and Candida albicans.
Ghannoum MA; Fu Y; Ibrahim AS; Mortara LA; Shafiq MC; Edwards JE; Criddle RS
Antimicrob Agents Chemother; 1995 Nov; 39(11):2459-65. PubMed ID: 8585726
[TBL] [Abstract][Full Text] [Related]
4. Combined in vitro activity of amphotericin B and 5-fluorocytosine against Cryptococcus neoformans and Candida albicans.
Chen HH; Liushih RN; Hsieh WC
Zhonghua Min Guo Wei Sheng Wu Ji Mian Yi Xue Za Zhi; 1982 May; 15(2):106-12. PubMed ID: 7047097
[TBL] [Abstract][Full Text] [Related]
5. Use of Pinus sylvestris L. (Pinaceae), Origanum vulgare L. (Lamiaceae), and Thymus vulgaris L. (Lamiaceae) essential oils and their main components to enhance itraconazole activity against azole susceptible/not-susceptible Cryptococcus neoformans strains.
Scalas D; Mandras N; Roana J; Tardugno R; Cuffini AM; Ghisetti V; Benvenuti S; Tullio V
BMC Complement Altern Med; 2018 May; 18(1):143. PubMed ID: 29724221
[TBL] [Abstract][Full Text] [Related]
6. In vitro antifungal synergy between amphiphilic aminoglycoside K20 and azoles against Candida species and Cryptococcus neoformans.
Shrestha SK; Grilley M; Anderson T; Dhiman C; Oblad J; Chang CW; Sorensen KN; Takemoto JY
Med Mycol; 2015 Nov; 53(8):837-44. PubMed ID: 26260746
[TBL] [Abstract][Full Text] [Related]
7. [Susceptibility of yeasts to antifungal agents in Kaunas University of Medicine Hospital].
Skrodeniene E; Dambrauskiene A; Vitkauskiene A
Medicina (Kaunas); 2006; 42(4):294-9. PubMed ID: 16687901
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of antifungal combination against Cryptococcus spp.
Reichert-Lima F; Busso-Lopes AF; Lyra L; Peron IH; Taguchi H; Mikami Y; Kamei K; Moretti ML; Schreiber AZ
Mycoses; 2016 Sep; 59(9):585-93. PubMed ID: 27135278
[TBL] [Abstract][Full Text] [Related]
9. In vitro activity of fluvastatin, a cholesterol-lowering agent, and synergy with flucanazole and itraconazole against Candida species and Cryptococcus neoformans.
Chin NX; Weitzman I; Della-Latta P
Antimicrob Agents Chemother; 1997 Apr; 41(4):850-2. PubMed ID: 9087504
[TBL] [Abstract][Full Text] [Related]
10. Synergistic effect of pyrvinium pamoate and posaconazole against
Li Y; Li S; Chen M; Xiao J; Fang H
Front Cell Infect Microbiol; 2022; 12():1074903. PubMed ID: 36569209
[TBL] [Abstract][Full Text] [Related]
11. Pneumocandin L-743,872 enhances the activities of amphotericin B and fluconazole against Cryptococcus neoformans in vitro.
Franzot SP; Casadevall A
Antimicrob Agents Chemother; 1997 Feb; 41(2):331-6. PubMed ID: 9021188
[TBL] [Abstract][Full Text] [Related]
12. The antiproliferative peptide Ctn[15-34] is active against multidrug-resistant yeasts Candida albicans and Cryptococcus neoformans.
de Aguiar FLL; Cavalcante CSDP; Dos Santos Fontenelle RO; Falcão CB; Andreu D; Rádis-Baptista G
J Appl Microbiol; 2020 Feb; 128(2):414-425. PubMed ID: 31626724
[TBL] [Abstract][Full Text] [Related]
13. Antifungal drug resistance in pathogenic fungi.
Vanden Bossche H; Dromer F; Improvisi I; Lozano-Chiu M; Rex JH; Sanglard D
Med Mycol; 1998; 36 Suppl 1():119-28. PubMed ID: 9988500
[TBL] [Abstract][Full Text] [Related]
14. [Short communication: In vitro activity of amphotericin B with fluconazole or voriconazole combinations against Candida albicans isolates].
Oz Y; Akşit F; Kiraz N; Kiremitçi A
Mikrobiyol Bul; 2008 Jan; 42(1):149-55. PubMed ID: 18444574
[TBL] [Abstract][Full Text] [Related]
15. In vitro activity of voriconazole and amphotericin B against Candida albicans, Candida krusei, and Cryptococcus neoformans in human cerebrospinal fluid.
Al Jalali V; Sauermann R; Eberl S; Zeitlinger M
Infection; 2019 Aug; 47(4):565-570. PubMed ID: 30725316
[TBL] [Abstract][Full Text] [Related]
16. In vitro activities of posaconazole (Sch 56592) compared with those of itraconazole and fluconazole against 3,685 clinical isolates of Candida spp. and Cryptococcus neoformans.
Pfaller MA; Messer SA; Hollis RJ; Jones RN
Antimicrob Agents Chemother; 2001 Oct; 45(10):2862-4. PubMed ID: 11557481
[TBL] [Abstract][Full Text] [Related]
17. In-vitro activity of dicationic aromatic compounds and fluconazole against Cryptococcus neoformans and Candida spp.
Del Poeta M; Bixel AS; Barchiesi F; Tidwell RR; Boykin D; Scalise G; Perfect JR
J Antimicrob Chemother; 1999 Aug; 44(2):223-8. PubMed ID: 10473229
[TBL] [Abstract][Full Text] [Related]
18. In vitro susceptibility of 119 yeast isolates to fluconazole, 5-fluorocytosine, amphotericin B and ketoconazole.
Morace G; Manzara S; Dettori G
Chemotherapy; 1991; 37(1):23-31. PubMed ID: 2013239
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of Novel Schiff base Derivatives as Antifungal Compounds in Combination with Approved Drugs Against Candida Albicans.
Malik MA; Lone SA; Gull P; Dar OA; Wani MY; Ahmad A; Hashmi AA
Med Chem; 2019; 15(6):648-658. PubMed ID: 30501599
[TBL] [Abstract][Full Text] [Related]
20. Lactoferrin Is Broadly Active against Yeasts and Highly Synergistic with Amphotericin B.
Fernandes KE; Weeks K; Carter DA
Antimicrob Agents Chemother; 2020 Apr; 64(5):. PubMed ID: 32094132
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
